Last updated: October 15, 2026
CAPOZIDE 25/25 is a fixed-dose antihypertensive containing 25 mg of captopril and 25 mg of hydrochlorothiazide. Its commercial trajectory is that of a mature, largely discontinued brand whose therapeutic components became low-cost generics decades ago. The product has no meaningful remaining exclusivity, no biosimilar pathway, and limited standalone revenue visibility. Any current commercial value is primarily tied to generic availability, legacy prescribing, and the separate captopril and hydrochlorothiazide markets.
What is CAPOZIDE 25/25?
CAPOZIDE 25/25 combines:
| Attribute |
Detail |
| Brand |
CAPOZIDE |
| Strength |
25 mg captopril / 25 mg hydrochlorothiazide |
| Drug class |
ACE inhibitor plus thiazide diuretic |
| Original manufacturer |
Bristol-Myers Squibb |
| Dosage form |
Immediate-release oral tablet |
| Primary indication |
Hypertension |
| Regulatory status |
Legacy product; no meaningful current brand exclusivity |
| Biologic status |
Small-molecule drug; biosimilar rules do not apply |
| Commercial position |
Mature, low-value combination product |
Captopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation. Hydrochlorothiazide promotes sodium and fluid excretion. The combination was designed to provide complementary blood-pressure control in patients who required more than one antihypertensive agent (Bristol-Myers Squibb, 2006).
The 25/25 strength is one of several historical CAPOZIDE presentations. The product line also included combinations using 15 mg or 25 mg of hydrochlorothiazide with either 25 mg or 50 mg of captopril.
When did CAPOZIDE 25/25 lose exclusivity?
CAPOZIDE 25/25 lost practical market exclusivity in the 1990s or earlier as the underlying active ingredients and combination technology entered the generic market. Captopril was approved in the early 1980s, while hydrochlorothiazide had already been used as a longstanding generic diuretic. Any original patent protection associated with the active ingredients would have expired long before the current market period.
| Exclusivity category |
CAPOZIDE 25/25 status |
| New chemical entity exclusivity |
Expired |
| Original compound patents |
Expired |
| Fixed-dose combination patents |
Expired or commercially irrelevant |
| Pediatric exclusivity |
None relevant |
| Orphan exclusivity |
None |
| Reference-product exclusivity |
No current commercial significance |
| Biosimilar exclusivity |
Not applicable |
| Current market exclusivity |
None identified |
The relevant competitive barrier is therefore not patent protection. It is the economics of manufacturing, regulatory maintenance, distribution and physician demand.
What is the FDA regulatory status of CAPOZIDE 25/25?
CAPOZIDE is a historical FDA-approved prescription product. Its original labeling covered hypertension and included warnings associated with both ACE inhibitors and thiazide diuretics, including fetal toxicity, hyperkalemia, renal impairment, hypotension and angioedema (Bristol-Myers Squibb, 2006).
The brand should be treated as a legacy product rather than an actively promoted growth asset. FDA discontinuation records and current commercial databases may show different status labels depending on whether they refer to the brand NDA, a specific package configuration or a later generic equivalent. A product being listed as discontinued does not by itself establish a safety withdrawal.
Is CAPOZIDE 25/25 listed in the Orange Book?
The Orange Book is the relevant FDA source for approved drug products, therapeutic-equivalence evaluations and certain patent or exclusivity information. For a legacy product such as CAPOZIDE 25/25, the commercial implication is limited because:
- Any original listed patents have long since expired.
- Brand-level exclusivity does not block generic captopril or hydrochlorothiazide.
- Generic substitution economics are driven by low acquisition cost.
- The product is not protected by biologic reference-product rules.
Orange Book status should be checked by exact NDA, strength and dosage form because legacy listings can differ from active commercial availability (U.S. Food and Drug Administration, 2025a).
What patents protect CAPOZIDE 25/25?
No active patent estate appears to protect the commercial use of CAPOZIDE 25/25 as a branded product. The principal patent barriers associated with captopril and hydrochlorothiazide expired decades ago.
Patent categories relevant to the product
| Patent category |
Current commercial effect |
| Captopril compound patents |
Expired |
| Hydrochlorothiazide compound patents |
Expired |
| Fixed-dose combination patents |
Expired or no longer commercially material |
| Tablet formulation patents |
No identified blocking position |
| Method-of-use patents |
No commercially meaningful exclusivity |
| Manufacturing patents |
Potentially relevant to cost, not market access |
| Packaging or dosage patents |
No practical exclusivity |
The product does not depend on a modern delivery system, complex formulation, device, sterile manufacturing process or biological production platform. Its active ingredients are conventional small molecules manufactured through established chemical processes.
Are there Paragraph IV challenges to CAPOZIDE 25/25?
Paragraph IV litigation is not a current commercial issue for CAPOZIDE 25/25. Paragraph IV certifications apply when an abbreviated new drug application applicant challenges an allegedly unexpired patent listed for a reference product. For this legacy combination, the relevant patent terms have expired or no longer create a meaningful barrier.
The likely historical generic pathway was based on ordinary ANDA approval and therapeutic equivalence rather than an active patent dispute. Generic applicants would have had limited incentive to litigate against a brand with an aging market, low prices and declining prescription volume.
No current Paragraph IV case is material to the commercial outlook of CAPOZIDE 25/25 based on the product’s long-established generic status.
What formulations are protected by CAPOZIDE patents?
The 25/25 tablet is an immediate-release oral formulation. It does not have the formulation complexity associated with extended-release products, transdermal systems, inhaled medicines or injectable biologics.
The formulation contains:
- Captopril at 25 mg
- Hydrochlorothiazide at 25 mg
- Conventional tablet excipients
- Oral immediate-release delivery
Formulation protection, if any existed historically, would have been narrow and time-limited. The active ingredients can be administered separately, and physicians can substitute individual generic products when the fixed-dose combination is unavailable. That substitution option weakens the commercial value of any residual combination-product positioning.
How strong is the CAPOZIDE 25/25 patent estate?
The current patent estate is weak from a market-exclusivity perspective.
| Strength factor |
Assessment |
| Remaining patent term |
None of commercial importance |
| Claim scope |
Narrow or expired |
| Formulation complexity |
Low |
| Active-ingredient scarcity |
None |
| Manufacturing difficulty |
Low to moderate |
| Substitution risk |
High |
| Generic price pressure |
High |
| Litigation leverage |
Minimal |
| Licensing value |
Minimal |
The product may still have technical manufacturing requirements involving stability, impurity controls and tablet uniformity. Those requirements can create operational barriers for small manufacturers, but they do not create enforceable market exclusivity.
How has the market for CAPOZIDE 25/25 changed?
The antihypertensive market moved away from older ACE inhibitor-thiazide brands toward generic monotherapies, newer fixed-dose combinations and alternative guideline-driven regimens.
Key market pressures include:
- Generic substitution. Captopril and hydrochlorothiazide are inexpensive, widely understood molecules.
- Prescribing simplification. Physicians may select newer fixed-dose combinations with once-daily dosing.
- Competing ACE inhibitor products. Lisinopril, enalapril and benazepril have broader contemporary use in many markets.
- Angiotensin receptor blockers. Losartan, valsartan and related products compete where cough or ACE-inhibitor intolerance is a concern.
- Separate-component prescribing. Clinicians can titrate captopril and hydrochlorothiazide independently.
- Limited brand support. A discontinued or minimally promoted brand cannot sustain premium pricing.
Captopril also has a shorter dosing interval than several later ACE inhibitors. That characteristic can reduce its attractiveness in routine hypertension management, although it remains clinically useful in selected settings.
What is the financial trajectory of CAPOZIDE 25/25?
CAPOZIDE 25/25 has followed a typical late-life pharmaceutical trajectory:
| Period |
Financial profile |
| Initial launch period |
Premium branded pricing and physician promotion |
| Early generic-entry period |
Rapid price and volume erosion |
| Mature generic period |
Low unit prices and fragmented supply |
| Late brand period |
Declining sales, limited promotion and discontinuation risk |
| Current period |
Minimal standalone brand value; commodity-like economics |
Bristol-Myers Squibb did not report CAPOZIDE revenue as a separate material line item in its public financial reporting. The product was historically grouped within broader cardiovascular or pharmaceutical revenue categories. Public filings therefore do not support a reliable product-specific revenue series.
The financial value of CAPOZIDE 25/25 is best assessed through market structure rather than historic brand sales:
- Price: low
- Gross margin: compressed
- Patient volume: likely small relative to newer antihypertensive products
- Promotional spending: negligible
- Patent-adjusted value: effectively zero
- Licensing value: low
- Manufacturing value: dependent on scale and supply efficiency
A company acquiring rights to the brand would gain little from patent protection. The commercial case would require low-cost manufacturing, an established generic distribution network or a portfolio strategy involving several mature cardiovascular products.
Which companies challenge CAPOZIDE 25/25 commercially?
The competitive threat comes primarily from manufacturers of generic captopril, hydrochlorothiazide and other antihypertensive combinations. Competition is not limited to identical 25/25 tablets.
Direct competitors
- Generic captopril/hydrochlorothiazide tablets
- Separate generic captopril and hydrochlorothiazide products
- Other ACE inhibitor-thiazide combinations
Therapeutic competitors
- Lisinopril/hydrochlorothiazide
- Enalapril/hydrochlorothiazide
- Losartan/hydrochlorothiazide
- Valsartan/hydrochlorothiazide
- Benazepril/hydrochlorothiazide
- Generic single-agent ACE inhibitors
- Generic thiazide and thiazide-like diuretics
Direct generic suppliers can compete on price and availability. Therapeutic competitors can replace the product entirely, which increases demand elasticity and limits pricing power.
What generic entry risks exist for CAPOZIDE 25/25?
Generic-entry risk is no longer a future event. It is the defining condition of the product’s current market.
| Risk |
Impact |
| Additional ANDA approvals |
Further price compression |
| Manufacturer exit |
Potential intermittent shortages |
| Wholesaler consolidation |
Lower supplier leverage |
| Low prescription volume |
Reduced production incentives |
| Separate-component substitution |
Lower fixed-dose demand |
| Competing combinations |
Volume displacement |
| Reimbursement restrictions |
Limited brand reimbursement |
The principal risk for a remaining CAPOZIDE seller is not generic launch. It is market abandonment caused by low margins and insufficient volume. If supply becomes scarce, prescribers can generally substitute separate captopril and hydrochlorothiazide products or select another combination.
What patent litigation or settlement agreements affect CAPOZIDE 25/25?
No current litigation or settlement agreement is commercially material to CAPOZIDE 25/25. The product’s age and expired exclusivity reduce the probability that a new patent dispute would affect market access.
Historical litigation may exist in archived federal court records, FDA submissions or patent databases, but any such dispute would have to be evaluated against the current absence of enforceable exclusivity. A settlement involving a long-expired CAPOZIDE patent would not ordinarily change present-day entry conditions.
Does CAPOZIDE 25/25 have biosimilar risk?
No. CAPOZIDE 25/25 is a small-molecule tablet, not a biologic. Biosimilars are therefore irrelevant. The applicable competitive framework is generic-drug substitution under the ANDA pathway, not the abbreviated biologics license application pathway under the Public Health Service Act.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are modest but not zero. A supplier must maintain:
- Valid cGMP compliance
- Assay and content-uniformity controls
- Stability data
- Impurity specifications
- Packaging suitable for product stability
- FDA-approved labeling and manufacturing sites
- Reliable active pharmaceutical ingredient supply
These requirements affect operational execution. They do not support premium pricing or block generic entry. Captopril and hydrochlorothiazide are established APIs with multiple potential sources, and the tablet does not require specialized equipment comparable to inhaled, injectable or biologic products.
How does CAPOZIDE 25/25 compare with newer antihypertensive combinations?
| Factor |
CAPOZIDE 25/25 |
Newer fixed-dose combinations |
| Active ingredients |
Captopril/HCTZ |
Often ARB/HCTZ or later ACE inhibitor/HCTZ |
| Dosing convenience |
Less favorable in many patients |
Often once daily |
| Patent position |
Expired |
May include limited remaining formulation or product patents |
| Brand value |
Minimal |
Varies by product age |
| Generic competition |
Extensive |
Depends on product |
| Pricing power |
Very low |
Higher before generic entry |
| Clinical differentiation |
Limited |
May include tolerability or convenience advantages |
| Commercial growth |
Unlikely |
Possible for newer or differentiated products |
CAPOZIDE 25/25 can remain clinically interchangeable with other established regimens for appropriate patients, but it has little strategic advantage in a crowded antihypertensive market.
What are the likely generic launch scenarios?
The most plausible commercial scenarios are:
Scenario 1: Continued low-volume generic supply
A small number of manufacturers continue supplying the product at low prices. This is the most likely steady-state outcome if demand remains sufficient to cover manufacturing and regulatory costs.
Scenario 2: Brand disappearance with separate-component substitution
The fixed-dose product becomes unavailable, while captopril and hydrochlorothiazide remain available separately. This scenario preserves therapeutic access but eliminates the brand’s commercial relevance.
Scenario 3: Intermittent shortage
One or more suppliers exit, creating temporary supply gaps. Pharmacies substitute another manufacturer, separate components or a different antihypertensive combination.
Scenario 4: Portfolio-only relaunch
A generic company revives the product as part of a broader mature-drug portfolio. Such a relaunch would depend on low manufacturing cost and distribution access, not patent protection.
Key Takeaways
- CAPOZIDE 25/25 contains 25 mg of captopril and 25 mg of hydrochlorothiazide.
- The product is a legacy small-molecule antihypertensive with no meaningful remaining exclusivity.
- Its patent estate is commercially weak because compound and combination protection expired long ago.
- Paragraph IV litigation, biosimilar competition and current patent settlements are not material market factors.
- Product-specific revenue was not separately disclosed by Bristol-Myers Squibb.
- The financial trajectory is consistent with rapid post-generic erosion, low pricing power and limited standalone value.
- The main competitive threats are generic substitution, separate-component prescribing and newer antihypertensive combinations.
- Manufacturing barriers are operational rather than proprietary.
- The most likely future is low-volume generic availability, intermittent supply or complete brand disappearance.
FAQs About CAPOZIDE 25/25
Is CAPOZIDE 25/25 still prescribed?
It may remain available through legacy or generic channels, but it is not a major contemporary branded antihypertensive product. Prescribers can use separate captopril and hydrochlorothiazide or alternative fixed-dose combinations.
What is the generic equivalent of CAPOZIDE 25/25?
The generic equivalent is a tablet containing captopril 25 mg and hydrochlorothiazide 25 mg. Availability depends on the manufacturer and national market.
Is CAPOZIDE 25/25 more valuable as a brand or as a generic?
Its value is greater as a low-cost generic portfolio product than as a branded asset. There is no apparent patent-based premium.
Can CAPOZIDE 25/25 be replaced by separate tablets?
In clinical practice, the two active ingredients can generally be prescribed separately when appropriate. Dose selection and patient monitoring remain clinical decisions.
What would make CAPOZIDE 25/25 commercially attractive again?
A relaunch would require reliable low-cost supply, reimbursement access, distribution scale and a clear supply gap. New patent protection or exclusivity is not a realistic source of value.
References
-
Bristol-Myers Squibb. (2006). Capozide captopril and hydrochlorothiazide tablets: Prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugsatfda
-
U.S. Food and Drug Administration. (2025b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2025c). FDA drug establishment and product databases. https://www.fda.gov/drugs
-
U.S. Food and Drug Administration. (2025d). Approved drug product list and discontinued drug product information. https://www.fda.gov/drugs/drug-approvals-and-databases
